Weicheng Pharmaceuticals key facts
- Developer of a proprietary extrahepatic drug delivery platform designed to advance targeted small nucleic acid therapies beyond hepatic tissues.
- It has raised $64.0M; the latest was Early Stage VC ($54.0M) in Apr 2026.
- Notable investors include Qiming Venture Partners, Highlight Capital, Apricot Capital (Shanghai), TF Capital.
- Status: Privately Held (backing).
Who backs Weicheng Pharmaceuticals
4Weicheng Pharmaceuticals funding rounds
No funding rounds for Weicheng Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Weicheng Pharmaceuticals investors
4 investors are on record for Weicheng Pharmaceuticals, including Qiming Venture Partners, Highlight Capital, Apricot Capital (Shanghai) and TF Capital.
About Weicheng Pharmaceuticals
Developer of a proprietary extrahepatic drug delivery platform designed to advance targeted small nucleic acid therapies beyond hepatic tissues. The company offers specialized delivery mechanisms and preclinical pipeline innovations, enabling biotechnology developers focused on non-hepatic conditions to address critical therapeutic gaps with enhanced precision.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2025
- Ownership
- Privately Held (backing)
Is this your company? Profiles are maintained at PrivateMarketView, the data platform behind this page — sign in with your work email to keep it current, or tell us what's wrong.
Weicheng Pharmaceuticals doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.